**Minutes ORF Meeting 20th September 2017-Prague**

**Present**, Herve Finel, Peter Dreger, Silvia Montoto, Stephen Robinson, Luca Castagna, Claire Burney, Harry Schouten, Marek Trneny, Chara Kyriakou, Stefania Bramanti, Tsvetkova Liubov, Leyre Bento, Sonya Stavrika, Mikhail Uvarov, Elisabett Xue, Robert Lown, Petra Vockova, Kamila Polgarova, Jan Molinsky, Ambree Sherkle, Alexsei Titov, Karen Meliksetyou, Ali Bazarbachi, Christian Gisselbrecht

**Apologies**

Erik Aerts, Ariane Boumendil, Olivier Hermine, Alina Tanase, Anna Sureda, Sascha Dietrich

**LWP Activity**

* Proposed timelines for studies
* 13 studies approved/launched: 5 ongoing, 7 finished, 1 to be launched
* Approval to launching: 1-15 months, median 8 months
* 7 studies finished, from launching to data completed: 1-8 months, median 7 months
* 5 ongoing launched between April and Sept 2017

**General Matters**

* Annual meeting program **Lisbon 2018**

**Lymphoma Related Educatonal Sessions**

1. High Grade Lymphoma (Noel Milpied, France)
2. Follicular Lymphoma (Silvia Montoto, UK)
3. Hodgkin’s lymphoma (Anna Sureda Spain)
4. Immune checkpoint inhibitors in lymphoma (M. Perales US)

**Workshop**

Haplo versus siblings in Hodgkin disease (J Gayoso, Spain)

**Meet The Expert**

1. Maintenance Therapy in Hodgkin’s Lymphoma (Anna Sureda, Spain)
2. Treatment of Richters syndrome (Peter Dreger, Germany)

* **LWP Session** (Tuesday, March 20th 2018, 11:00 - 12:30, Auditorium 2 (380 pax; level 1)

11,05-11,15: Highlights of the LWP activity

11,15-11,20: LWP Educational Course 2018

11,20-11,25: presentation of Jian-jian Luan award winner

11,25-11,40: lecture of the Jian-jian Luan award abstract

11,40-12,25: LWP keynote debate: Should we choose an haplo over a 10/10 donor in NHL?

11,40-11,55: No (N Schmitz)

11,55-12,10: Yes (L Castagna)

12,10-12,25: Discussion

12,25-12,30: Concluding remarks

* **SOP for interWP studies** (SM). A proposal regarding this was presented by Silvia Montoto. Suggestions and comments will be incorporated and taken to the EBMT SC.

**Educational Issues**

* Status Ed Course 2018
* Palma de Mallorca 26, 27, 28th September 2018
* General discussion about the optimal dates for the autumn meeting so that it does not clash with other meetings
* Bids for 2019: Bristol
* Speakers travel costs. Need to cover cost of flights and be permissive. Speakers should attempt to follow the guidelines regarding costs and book flights early. The chair should consider travel costs in excess of guidelines on an individual basis.

**Manuscript status (analysis completed)**

* 1998-P-01 Lym long F/U **(RP/SM)**
* 2006-R-02 RIC in MCL (**SR**), **rejected Ann Oncol/Cancer, submitted to BMT (16/8/17)**
* 2007-R-01 HL auto late effects update (**AS/PD**), paper to be circulated to WC/authors
* 2009-R-06 FL unrelated; **AS with CIBMTR, Rejected by JCO/AO, submitted to Cancer (10/9/17)**
* 2010-N-02 WM auto; **CK**, 1st draft written and with SM
* 2011-R-01 PMBCL auto; **IA**, **accepted BMT (20/9/17)**
* 2012-R-04 MALT; **AC/SM**, paper with SM and to be to be circulated WC/authors
* 2012-R-02E CTCL recent era; **RD/ED**, 1st draft being written, to be circulated to WC, then co-authors
* 2013-N-02i PWI prior to SCT; **PD**, 1st draft with co-authors for Blood
* 2013-C-01 WM consensus in WM; submitted to ASH(CK)- **paper 2018**
* 2014-R-01 alloWM (**CK**); MS being prepared by CK *for JCO?*
* 2015-R-03 Rel after auto DLBCL (AS)-submitted to ASH then for **paper 2018**
* 2015-R-04 HIV new era (**KH**); draft with WC and awaiting more analysis, for JCO
* 2015-R-05 Allo in NHL according to age; **CK/PD**, 1st draft written and new analysis being added, with CK/PD for BBMT/BMT
* 2015-R-06 SCT in NLP-HL (**SA/AS**), **rejected JCO/Blood/AO; submitted to AJH 6/9/17**
* 2015-R-01A BV as bridge to SCT in ALCL (AS/ED)-two papers (auto and allo) **papers 2018**
* 2015-R-01H BV as bridge to SCT in HL (**AB/AS**), **rejected by JCO. To submit to Blood**
* 2015-R-08 Haplo in DLBCL (PD/AS with CIBMTR who are still analysing the paper)
* 2015-R-09 FL Rel post auto in FL (SR) submitted to ASH- **paper 2018**
* 2016-R-05 BEAC toxicity **(SR);** **submitted to BMT**

**Ongoing LWP studies –data collection**

* 2009-N-02 SCT in blastic plasmocytoid dendritic cell neoplasia (SD with ALWP) **28 LWP** (prosp) **+ 151 ALWP** (retrosp). These will need histological review of histology reports.
* 2016-S-01 Checkpoint inhibitors pre/post alloHCT- **post allo** **22 pts (2 NHL, 20 HL).**
* 2016-other PI studies with CMWP (PD). All data collected by CMWP and others, but will be analysed by the LWP
* Lymphoma and CLL ibrut, idela, veneto peri-alloSCT
* Idela post FLL and other lymphoma 29 patients
* Idela pre allo for FL- ASH abstract
* 92 pateints 50 with NHL
* 2016-R-02 DLI in lymphoma (SR). Received data on 281 of 792 potential patients
* 2016-R-04 2nd auto in HL (CM/AS)
* 2017-R-02 haplo (AB/AS). Launched 2 weeks ago. More than 200 patients pledged so far.

**Ongoing LWP studies –data analysis**

* 1998-P-01 Lym1-long follow up (RP/SM)- Presented at Lugano 2017. Dataset with AB and will be analysed over next 2-3 weeks. Paper 2018 aim for JCO2017-R-01
* Trends in SCT in FL (SR). Analysis completed.

**Abstracts for 2017/2018**

Submitted to ASH 2017

* 2013-N-02i PWI prior to SCT (PD) -1st draft for Blood
* 2013-C-01 WM consensus in WM (CK) -paper 2018
* 2015-R-03 Rel after auto DLBCL (AS)-paper 2018
* 2015-R-09 FL Rel post auto in FL (SR)- paper 2018

EBMT 2018 (deadline Dec 2017)

* 2013-C-01 WM consensus (CK)
* 2017-R-01 Trends in SCT in FL (SR)
* 2009 –N-02 BPDCN Will need histological review first??
* 2016-S01 CI pre alloSCT (SD/AS/PD)??
* 2016-R-03 Trends in SCT in HL (AS/SG) No proposal received??

EHA 2018 (deadline March 2018)

* CI post alloSCT
* DLI in lymphoma
* 2nd autoSCT in HL

**New proposals**

* 2016-R-03 Trends in SCT in HL (AS/SG). This was approved in Sept 2016. No proposal received yet. 6 votes for a priority, 1 intermediate, 0 back of queue.
* EBMT database request on the use of BCNU and thiotepa in preparative regimens for hematopoietic cell transplantation in patients with lymphoma (PD). This is a commercial study sponsored by Reimser. In line with EBMT recommendations. Requires info on numbers of BCNU based transplants by country and type of SCT (auto or allo).
* Post-transplant cyclophosphamide-based (PT-Cy) GVHD prophylaxis compared to standard CNI-based (calcineurin-inhibitors) GVHD prophylaxis in lymphoma patients receiving sibling and unrelated HLA identical stem cell transplantation (HSCT): a retrospective study from the LWP of EBMT (S Bramanta/Luca Castagna). Approved by 14. No refusals. Normal priority study.

* Prospective observational study comparing transplantation from haploidentical donor to any other donor transplantation in Hodgkin lymphoma patients. An EBMT study (S Bramanta/Luca Castagna). Approved by 12, 1 no. Priority normal priority.
* EMBT LWP research proposal: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for Mantle Cell Lymphoma (SR/CB). Approved by 12. No refusals. Normal priority.

**Any other business**

**Next Meeting Lisbon 7am-9am March 20th 2018**